头孢哌酮钠舒巴坦联合依替米星治疗支气管扩张症的疗效分析

Curative effect of cefoperazone sodium combined with etimicin in bronchiectasis

目的:探讨头孢哌酮钠舒巴坦联合依替米星治疗支气管扩张症的临床疗效。方法:选取支气管扩张症伴绿脓杆菌感染患者120例,并分为对照组和实验组。其中对照组58例,单用头孢哌酮钠舒巴坦1.5 g每8小时1次静脉滴注治疗;实验组62例,头孢哌酮钠舒巴坦1.5 g每8小时1次静脉滴注,同时依替米星0.2 g每日1次静脉滴注治疗。治疗疗程均为2周,治疗结束后评估其临床疗效。结果:对照组有效42例,有效率72.4%;实验组有效53例,有效率85.5%。实验组较对照组临床有效率明显升高,差异具有统计学意义(P<0.05)。对照组细菌清除率为62.1%,实验组细菌清除率为83.9%。实验组较对照组细菌清除率明显升高,差异具有统计学意义(P<0.05)。对照组治疗后血白细胞值较治疗前有所下降,实验组治疗后血白细胞值较治疗前明显下降,且二者差异具有统计学意义(P<0.05)。结论:头孢哌酮钠舒巴坦联合依替米星治疗支气管扩张症伴绿脓杆菌感染的临床疗效好,细菌清除率高。

Objective： To investigate the curative effect of cefoperazone sodium combined with etimicin in bronchiectasis.Methods： 120 patients with bronchiectasis and infection of pseudomonas aeruginosa were randomly divided into control group（ 58 cases） and treatment group（ 62 cases）. The control group were given cefoperazone sodium treatment（ 1. 5 g intravenous infusion once every 8 hours）,the treatment group were given cefoperazone sodium（ 1. 5 g intravenous infusion once every 8hours） combined with etimicin（ 0. 2 g intravenous infusion once a day） treatment. After treatment of two weeks,evaluate the clinical effects. Results： The clinical effective rate was 72. 4% in control group and 85. 5% in treatment group,which was statistically significant difference（ P〈0. 05）. The Bacterial clearance rate was 62. 1% in control group and 83. 9% in treatment group,which was statistically significant difference（ P〈0. 05）. Compared with before treatment,the white blood cell values decreased after treatment both control group and treatment group,but only in treatment group,the change was statistically significant difference（ P〈0. 05）. Conclusion： Cefoperazone sodium combined with etimicin used to treat the patients with bronchiectasis and infection of pseudomonas aeruginosa had a linical effective and a high Bacterial clearance rate.